Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort. In this ...

Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an ...

New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO ...

Two global partnerships surfaced across metabolic disease and oncology this week, as Novo and AstraZeneca each moved to expand their pipelines through deals with clinical-stage in ...

In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of seven nominated peptides, ...

Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient ...

Pharmaceutical Executive spoke with Michael Abrams, managing partner at global healthcare consultancy Numerof & Associates ...

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...

Incyte received a Rare Pediatric Disease Priority Review Voucher tied to zilurgisertib’s FOP approval, while Mirum plans U.S.